A new experimental study has shown early promise in tackling glioblastoma, one of the most aggressive and difficult-to-treat brain cancers, using a noninvasive nasal delivery approach that stimulates the immune system inside the brain.

Researchers from Washington University in St. Louis and collaborators in Japan developed a novel strategy to deliver immune-activating compounds through the nasal pathway, bypassing the need for direct brain surgery. The approach is designed to overcome two major obstacles in glioblastoma treatment: the blood-brain barrier and the tumor’s ability to suppress immune responses.

The team engineered STING-activating molecules into spherical nucleic acids arranged around gold nanoparticles. This structure protects the therapeutic agents from breaking down too quickly and improves their ability to reach the brain through the nose-to-brain route.

In preclinical experiments published in the Proceedings of the National Academy of Sciences (PNAS) in 2025, the treatment triggered a strong immune response against tumor cells and significantly slowed cancer growth in mice models of glioblastoma.

However, researchers stress that the findings are still at an early stage and have only been tested in animals. Human clinical trials are required before any potential medical application, which could still be years away.

Despite the limitations, scientists believe the platform could eventually be combined with existing immunotherapy treatments, potentially improving outcomes for cancers that are currently resistant to conventional approaches.

The study represents an encouraging step forward in noninvasive brain cancer research, offering a new direction for future therapies.